Compare CXH & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CXH | NOTV |
|---|---|---|
| Founded | 1989 | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.4M | 12.7M |
| IPO Year | N/A | 1997 |
| Metric | CXH | NOTV |
|---|---|---|
| Price | $8.30 | $0.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 21.4K | ★ 553.8K |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 3.56% | N/A |
| EPS Growth | N/A | ★ 49.64 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | ★ $547,656,000.00 |
| Revenue This Year | N/A | $5.28 |
| Revenue Next Year | N/A | $5.42 |
| P/E Ratio | $35.94 | ★ N/A |
| Revenue Growth | N/A | ★ 511.19 |
| 52 Week Low | $7.34 | $0.25 |
| 52 Week High | $8.39 | $3.35 |
| Indicator | CXH | NOTV |
|---|---|---|
| Relative Strength Index (RSI) | 55.83 | 53.76 |
| Support Level | $7.94 | $0.26 |
| Resistance Level | N/A | $0.65 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 45.23 | 67.99 |
Mfs Investment Grade Municipal Trust is a United States-based diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowing for investment purposes, in tax-exempt bonds and tax-exempt notes.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.